Table I.
Clinicopathological characteristics in patients with NAC.
| Clinicopathological characteristics | Patients with pCR (n=12) | Patients with non-pCR (n=12) | P-value |
|---|---|---|---|
| Median age at diagnosis, median (range) | 46 (24–63) | 59 (37–74) | 0.04 |
| Menopausal status, n (%) | 0.21 | ||
| Premenopausal | 7 (58) | 3 (25) | |
| Postmenopausal | 5 (42) | 9 (75) | |
| Tumor size, cm, median (range) | 2.5 (1.1–6.4) | 3.2 (1.6–7.8) | 0.34 |
| Nodal status, n (%) | 1.00 | ||
| Negative | 6 (50) | 6 (50) | |
| Positive | 6 (50) | 6 (50) | |
| Clinical T, n (%) | 0.75 | ||
| T1 | 3 (25) | 2 (17) | |
| T2 | 8 (67) | 8 (67) | |
| T3 | 0 (0) | 1 (8) | |
| T4 | 1 (8) | 1 (8) | |
| Stage, n (%) | 0.54 | ||
| 1 | 2 (17) | 2 (17) | |
| 2 | 9 (75) | 7 (58) | |
| 3 | 1 (8) | 3 (25) | |
| Nuclear grade, n (%) | 0.17 | ||
| 1,2 | 5 (42) | 2 (17) | |
| 3 | 7 (58) | 10 (83) | |
| Ki67 labeling index, %, median (range) | 61 (30–97) | 65 (20–100) | 0.75 |
| NAC, n (%) | 1.00 | ||
| FEC followed by DOC | 9 (75) | 8 (67) | |
| PAC followed by FEC | 3 (25) | 3 (25) | |
| FEC | 0 (0) | 1 (8) |
pCR, pathological complete response; NAC, neoadjuvant chemotherapy; FEC, 5-fluorouracil, epirubicin and cyclophosphamide; DOC, docetaxel; PAC, paclitaxel.